Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Collaboration in the industry needs to be institutionalised to drive the growth.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New biotechnology product aims to be world's fastest automatic sanitary solution
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
